Back to top
more

Omega Therapeutics (OMGA)

(Delayed Data from NSDQ)

$1.04 USD

1.04
232,788

-0.07 (-6.31%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $1.05 +0.01 (0.96%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts See a 59.64% Upside in Omega Therapeutics, Inc. (OMGA): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 59.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

by Zacks Equity Research

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

by Zacks Equity Research

Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 48.23%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 48.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -3.23% and 13.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 135.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 229.3% upside potential for Omega Therapeutics, Inc. (OMGA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Encompass Health (EHC) Forms JV With NCH Healthcare in Naples

by Zacks Equity Research

The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).

Encompass Health (EHC) Plans to Distribute Enhabit Shares

by Zacks Equity Research

Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.

Should You Hold On to Teladoc Health (TDOC) Stock for Now?

by Zacks Equity Research

Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.

HCA Healthcare's (HCA) Galen College Adds 8th New Facility

by Zacks Equity Research

HCA Healthcare's (HCA) Galen College nursing campus addition comes when the country is suffering from a nursing shortage.

Here's Why Investors Should Bet on Cigna (CI) Stock Now

by Zacks Equity Research

Cigna (CI) expects 2022 medical customers to grow by a minimum of 725,000, suggesting an upside from the prior projection.

UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike

by Zacks Equity Research

UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.

Encompass Health (EHC) Updates 2022 Guidance: Dips 5.4%

by Zacks Equity Research

Encompass Health (EHC) expects to retain its cash dividend routine. However, the amount might decline to reflect the spin-off of the home health and hospice business.

Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?

by Zacks Equity Research

Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.

The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%

by Zacks Equity Research

The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.

Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.